Teacher Retirement System of Texas Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Teacher Retirement System of Texas increased its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 902.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 288,250 shares of the medical device company's stock after buying an additional 259,491 shares during the period. Teacher Retirement System of Texas owned about 0.07% of DexCom worth $19,685,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after purchasing an additional 56,094 shares in the last quarter. Norges Bank bought a new stake in shares of DexCom in the 4th quarter valued at about $385,367,000. Northern Trust Corp boosted its holdings in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after buying an additional 753,857 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of DexCom by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after buying an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership raised its stake in shares of DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company's stock worth $144,152,000 after acquiring an additional 201,181 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director directly owned 56,621 shares of the company's stock, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,190 shares of company stock worth $2,281,732 over the last three months. Company insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of DXCM traded down $0.85 during trading hours on Friday, hitting $82.73. The stock had a trading volume of 1,841,055 shares, compared to its average volume of 4,400,961. The firm has a 50-day moving average price of $83.26 and a 200 day moving average price of $79.79. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The firm has a market capitalization of $32.44 billion, a price-to-earnings ratio of 61.74, a PEG ratio of 1.77 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent analyst reports. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. The Goldman Sachs Group initiated coverage on DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Truist Financial assumed coverage on shares of DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 price objective on the stock. Finally, Citigroup reiterated a "buy" rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.